Taylor J S, Tofts P S, Port R, Evelhoch J L, Knopp M, Reddick W E, Runge V M, Mayr N
Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
J Magn Reson Imaging. 1999 Dec;10(6):903-7. doi: 10.1002/(sici)1522-2586(199912)10:6<903::aid-jmri1>3.0.co;2-a.
Dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) is a method of imaging the physiology of the microcirculation. A series of recent clinical studies have shown that DCE MRI can measure and predict tumor response to therapy. Recent advances in MR technology provide the enhanced spatial and temporal resolution that allow the application of this methodology in the management of cancer patients. The September issue of this journal provided a microcirculation section to update readers on this exciting and challenging topic. Evidence is mounting that DCE MRI-based measures correlate well with tumor angiogenesis. DCE MRI has already been shown in several types of tumors to correlate well with traditional outcome measures, such as histopathologic studies, and with survival. These new measures are sensitive to tumor physiology and to the pharmacokinetics of the contrast agent in individual tumors. Moreover, they can present anatomical images of tumor microcirculation at excellent spatial resolution. Several issues have emerged from recent international workshops that must be addressed to move this methodology into routine clinical practice. First, is complex modeling of DCE MRI really necessary to answer clinical questions reliably? Clinical research has shown that, for tumors such as bone sarcomas, reliable outcome measures of tumor response to chemotherapy can be extracted from DCE MRI by methods ranging from simple measures of enhancement to pharmacokinetic models. However, the use of similar methods to answer a different question-the differentiation of malignant from benign breast tumors-has yielded contradictory results. Thus, no simple, one-size-fits-all-tumors solution has yet been identified. Second, what is the most rational and reliable data collection procedure for the DCE MRI evaluation? Several groups have addressed population variations in some key variables, such as tumor T(1)0 (T(1) prior to contrast administration) and the arterial input function C(a)(t) for contrast agent, and how they influence the precision and accuracy of DCE MRI outcomes. However, despite these potential complications, clinical studies in this section show that some tumor types can be assessed by relatively simple dynamic measures and analyses. The clinical scenario and tumor type may well determine the required complexity of the DCE MRI exam procedure and its analysis. Finally, we suggest that a consensus on naming conventions (nomenclature) is needed to facilitate comparison and analysis of the results of studies conducted at different centers. J. Magn. Reson. Imaging 10:903-907, 1999.
动态对比增强磁共振成像(DCE MRI)是一种对微循环生理进行成像的方法。近期的一系列临床研究表明,DCE MRI能够测量并预测肿瘤对治疗的反应。磁共振技术的最新进展提供了更高的空间和时间分辨率,使得该方法能够应用于癌症患者的管理。本刊9月号设置了一个微循环专题,向读者介绍这一令人兴奋且具有挑战性的主题。越来越多的证据表明,基于DCE MRI的测量与肿瘤血管生成密切相关。在几种类型的肿瘤中,DCE MRI已被证明与传统的预后指标(如组织病理学研究)以及生存率密切相关。这些新指标对肿瘤生理以及造影剂在个体肿瘤中的药代动力学敏感。此外,它们能够以出色的空间分辨率呈现肿瘤微循环的解剖图像。近期的国际研讨会提出了几个必须解决的问题,以便将该方法应用于常规临床实践。首先,DCE MRI的复杂建模对于可靠地回答临床问题真的有必要吗?临床研究表明,对于骨肉瘤等肿瘤,通过从简单的强化测量到药代动力学模型等方法,可以从DCE MRI中提取肿瘤对化疗反应的可靠预后指标。然而,使用类似方法回答另一个问题——区分乳腺恶性肿瘤和良性肿瘤——却产生了相互矛盾的结果。因此,尚未找到一种简单的、适用于所有肿瘤的解决方案。其次,DCE MRI评估最合理、可靠的数据收集程序是什么?几个研究小组已经探讨了一些关键变量的人群差异,如肿瘤T(1)0(注射造影剂前的T(1))和造影剂的动脉输入函数C(a)(t),以及它们如何影响DCE MRI结果的精度和准确性。然而,尽管存在这些潜在的复杂性,本专题中的临床研究表明,一些肿瘤类型可以通过相对简单的动态测量和分析进行评估。临床情况和肿瘤类型很可能决定DCE MRI检查程序及其分析所需的复杂程度。最后,我们建议需要就命名规范(术语)达成共识,以促进不同中心开展的研究结果的比较和分析。《磁共振成像杂志》10:903 - 907, 1999年。